Inactive Instrument

Press Releases Pulmatrix Inc Nasdaq

Equities

US74584P1030

Press Releases

Unlock all the news: Be the first to know and act before the market!

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	May. 30	AQ
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine	May. 16	AQ
Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K	May. 15	PU
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 13	AQ
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives	Jan. 09	AQ
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 10	AQ
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine	23-09-20	AQ
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-24	AQ
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-11	AQ
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	23-07-12	AQ
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society	23-06-16	AQ
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention	23-05-24	PR
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update	23-05-15	AQ
Pulmatrix Supports World Asthma Day 2023	23-05-02	PR
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update	23-03-31	AQ
PULMATRIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	23-03-30	AQ
PULMATRIX, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-03-30	AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-06	AQ
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma	23-02-06	PR
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pulmatrix Inc Nasdaq

Equities

US74584P1030

Press Releases

Filters